The pharmaceutical and biotechnology sectors are witnessing a whirlwind of significant developments, from legal disputes over acquisition terms to pivotal personnel changes and strategic restructuring initiatives. These shifts are emblematic of an industry in constant evolution, driven by
BioMarin Pharmaceutical Inc. has made headlines with its announcement of a significant €60 million investment geared towards the expansion of its state-of-the-art facility located in Shanbally, Co. Cork. This ambitious expansion plan encompasses the construction of a new four-story laboratory b
Earlier this week, the U.S. Food and Drug Administration (FDA) unveiled its much-anticipated final guidance on predetermined change control plans (PCCPs) for devices incorporating artificial intelligence and machine learning (AI/ML) software. This guidance signifies a significant milestone in the
Synthetic biology represents a revolutionary discipline that applies engineering principles to biology, aiming to develop cells into sophisticated micro-factories capable of producing essential materials. With the potential to spearhead advancements across numerous industries—including medicine, a
The upstream bioprocessing market is experiencing unprecedented growth, driven by a confluence of factors that are reshaping the landscape of biopharmaceutical production. Valued at 22.79 billion USD in 2023, the market is projected to surge to 82.10 billion USD by 2032, expanding at a compound
Roche is making a bold move in the field of allogeneic cell therapy with its recent acquisition of Poseida Therapeutics, a San Diego-based biotech firm. This $1 billion upfront deal underscores Roche's commitment to expanding its portfolio in cell and gene therapies, particularly targeting
